NCT00043771已完成2 期
Multi-Center, Double-Blind Study to Compare the Effects of 30mg Qd Versus 15 Mg Bid of Tolvaptan in Congestive Heart Failure Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.10 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2002年5月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 10
研究概览
简要总结
Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (10)
Loading locations...
相似试验
招募中
不适用
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAHRandomized Controlled TrialPulmonary Arterial HypertensionNCT05569655Chinese Pulmonary Vascular Disease Research Group100
已完成
2 期
Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease AloneHeart FailureNCT01955694Bayer72
已完成
不适用
Effects of tolvaptan in congestive heart failure patients with renal dysfunctiocongestive heart failureJPRN-UMIN000005465Department of cardiology Osaka city university graduate school of medicine200
Unknown
4 期
Evaluating Iron Protein Succinylate Oral Solution in Treating Chronic Heart Failure and Iron DeficiencyIron-deficiencyChronic Heart FailureNCT03344523Lee's Pharmaceutical Limited600
已完成
不适用
A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart FailureDiastolic Heart FailureSystolic Heart FailureCongestive Heart FailureNCT02084992Tufts Medical Center212